Safety and Immunogenicity of Radiation-Attenuated PfSPZ Vaccine in Equatoguinean Infants, Children, and Adults
Authors:
- Said A. JongoSJSaid A. Jongo
- Vicente Urbano Nsue Ndong NchamaVNVicente Urbano Nsue Ndong Nchama
- L. W. Preston ChurchLCL. W. Preston Church
- Ally OlotuAOAlly Olotu
- Stephen R. ManockSMStephen R. Manock
- Tobias SchindlerTSTobias Schindler
- Ali MtoroAMAli Mtoro
- Natasha KcNKNatasha Kc
- Orrin DevinskyODOrrin Devinsky
- Elcin ZanEZElcin Zan
- Ali HamadAHAli Hamad
- Elizabeth NyakarunguENElizabeth Nyakarungu
Open Access
- 9 May 2023
- journal article
- research article
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 109 (1) , 138-146
Abstract
: The radiation-attenuated Plasmodium falciparum sporozoites (PfSPZ) Vaccine has demonstrated safety and immunogenicity in 5-month-old to 50-year-old Africans in multiple trials. Except for one, each trial has restricted enrollment to either infants and children or adults < 50 years old. This trial was conducted in Equatorial Guinea and assessed the safety, tolerability, and immunogenicity of three direct venous inoculations of 1.8 × 106 or 2.7 × 106 PfSPZ, of PfSPZ Vaccine, or normal saline administered at 8-week intervals in a randomized, double-blind, placebo-controlled trial stratified by age (6–11 months and 1–5, 6–10, 11–17, 18–35, and 36–61 years). All doses were successfully administered. In all, 192/207 injections (93%) in those aged 6–61 years were rated as causing no or mild pain. There were no significant differences in solicited adverse events (AEs) between vaccinees and controls in any age group (P ≥ 0.17). There were no significant differences between vaccinees and controls with respect to the rates or severity of unsolicited AEs or laboratory abnormalities. Development of antibodies to P. falciparum circumsporozoite protein occurred in 67/69 vaccinees (97%) and 0/15 controls. Median antibody levels were highest in infants and 1–5-year-olds and declined progressively with age. Antibody responses in children were greater than in adults protected against controlled human malaria infection. Robust immunogenicity, combined with a benign AE profile, indicates children are an ideal target for immunization with PfSPZ Vaccine.Keywords
This publication has 34 references indexed in Scilit:
- Protection against malaria at 1 year and immune correlates following PfSPZ vaccinationNature Medicine, 2016
- Weekly miscarriage rates in a community-based prospective cohort study in rural western KenyaBMJ Open, 2016
- Vaccination Triggers, Rather than Causes, SeizuresEpilepsy Currents, 2015
- Etiologies for Seizures Around the Time of VaccinationPediatrics, 2014
- Controlled Human Malaria Infection of Tanzanians by Intradermal Injection of Aseptic, Purified, Cryopreserved Plasmodium falciparum SporozoitesThe American Journal of Tropical Medicine and Hygiene, 2014
- Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite VaccineScience, 2013
- Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based studyThe Lancet Infectious Diseases, 2012
- First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African ChildrenNew England Journal of Medicine, 2011
- Development of a metabolically active, non-replicating sporozoite vaccine to preventPlasmodium falciparummalariaHuman Vaccines, 2010
- Vaccination, seizures and ‘vaccine damage’Current Opinion in Neurology, 2007